Most Recent
Pharmacor is resisting AstraZeneca’s notice to produce in an intellectual property fight over diabetes drug Forxiga, claiming privilege over material evidencing its consideration of a new claim challenging the validity of a patent extension.
Saying swear words are now part of the common vernacular, IP Australia has cleared a vitamin company's foul- mouthed trademark for registration, on the proviso that the branding is restricted to goods aimed at adults.
Bupa has hit back at a class action alleging it provided poor quality care to residents at its aged care facilities, saying it was "not appropriate" to run the case as a group proceeding.
A class action against Allergan over recalled breast implants has asked a court to slash parts of the US pharma company’s defence, saying they are "incoherent".
The Full Court has rejected Medibank's bid to appeal a finding that legal professional privilege did not attach to a Deloitte report commissioned in the wake of a massive data breach.
A judge has refused to disqualify himself from case managing Mayne Pharma's latest dispute with US drug maker Cosette over the collapse of their $672 million merger agreement, calling the bid “plainly premature”.
NDIS-registered healthcare equipment provider Aidacare has admitted it likely breached the Australian Consumer Law with representations made about customers' consumer guarantee rights.
Medibank has criticised a judge’s finding that legal professional privilege did not attach to a Deloitte report commissioned in the wake of a massive data breach, arguing she came to an “illogical” conclusion.
Wotton Kearney has bolstered its health practice with the appointment of former Makinson D’Apice partner Eliza Faulk and her team of six.
The High Court has agreed to hear Otsuka's appeal of a decision that revoked its Abilify patent extension, which Otsuka argued would “lead to a groundswell of court proceedings”.